You are here: Industry Insights > INO-4800

News List

INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19 prnasia
December 08, 2020
INOVIO announced it has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE (INovio INO-4800 Vaccine Trial for Efficacy).
Keneka Eurogentec Joins Inovio’s Global Mfg. Consortium contractpharma
December 07, 2020
Inovio, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, has executed an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation ...
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A. prnasia
December 04, 2020
INOVIO announced the execution of an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, for Eurogentec to manufacture INOVIO's COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales.
Inovio to start mid-stage trials of its COVID-19 vaccine expresspharma
November 18, 2020
The US FDA had put Phase 3 of the mid-to-late stage trial on hold, and sought more information, including details on a delivery device used to inject genetic material into cells.
Second wave of COVID-19 vaccines may not be needed to reach higher efficacy bar than first batch expresspharma
October 26, 2020
It would be best for second wave vaccines to underscore ideal subpopulations or manufacturing and storage advantages that could underscore uptake.
COVID-19 DNA Vaccine Targeting SARS-CoV-2 Proven Effective in Non-Human Primates americanpharmaceuticalreview
August 06, 2020
INOVIO announced its COVID-19 DNA vaccine INO-4800 targeting SARS-CoV-2 was effective in protecting non-human primates (NHPs; specifically rhesus macaques) from live virus challenge 13 weeks after the last vaccination.
INOVIO’s COVID-19 DNA Vax Effective in NHP contractpharma
July 31, 2020
INO-4800 effective in protecting non-human primates from live virus challenge 13 weeks after the last vaccination.
INOVIO Announces Positive Interim Phase 1 Data for INO-4800 Vaccine for COVID-19 americanpharmaceuticalreview
July 09, 2020
INOVIO announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts.
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine americanpharmaceuticalreview
May 07, 2020
INOVIO has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG.
Inovio Pharmaceuticals boosts Covid-19 vaccine manufacturing pharmaceutical-technology
May 04, 2020
Inovio Pharmaceuticals has signed an agreement with German contract manufacturer Richter-Helm BioLogics for large-scale production of Covid-19 DNA vaccine candidate, INO-4800.

Previous page 1 2 3 4 Next page